Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...

Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $2.00. The ...

A captivating cricket match unfolded between Hottentots Holland and Victoria cricket clubs in a First Division A clash, with Victoria ultimately clinching a hard-fought victory at the Naval Sports ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting ...

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to ...